Good_老虎社区_美港股上老虎

MiniT00ns
2021-04-18

Good

Why Bionano Genomics Stock Is Tumbling Today

No news; just run-of-the-mill volatility.

Why Bionano Genomics Stock Is Tumbling Today

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":379694277,"tweetId":"379694277","gmtCreate":1618724308299,"gmtModify":1634291235395,"author":{"id":3581471313908104,"idStr":"3581471313908104","authorId":3581471313908104,"authorIdStr":"3581471313908104","name":"MiniT00ns","avatar":"https://static.tigerbbs.com/befdc6f780491346d85acccdfa4922c1","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Good</p></body></html>","htmlText":"<html><head></head><body><p>Good</p></body></html>","text":"Good","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/379694277","repostId":2127485530,"repostType":4,"repost":{"id":"2127485530","kind":"highlight","pubTimestamp":1618585200,"share":"https://ttm.financial/m/news/2127485530?lang=&edition=full","pubTime":"2021-04-16 23:00","market":"us","language":"en","title":"Why Bionano Genomics Stock Is Tumbling Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2127485530","media":"Motley Fool","summary":"No news; just run-of-the-mill volatility.","content":"<h3>What happened</h3>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></b> (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.</p>\n<h3>So what</h3>\n<p>When a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.</p>\n<p><img src=\"https://static.tigerbbs.com/dcfc4d284a25e006effaad0ea287adf6\" tg-width=\"700\" tg-height=\"451\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Saphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes).&nbsp;Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly <a href=\"https://laohu8.com/S/AONE\">one</a>-third.</p>\n<p>Bionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.</p>\n<h3>Now what</h3>\n<p>One of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.</p>\n<p>Bionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Bionano Genomics Stock Is Tumbling Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Bionano Genomics Stock Is Tumbling Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 23:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://www.fool.com/investing/2021/04/16/why-bionano-genomics-stock-is-tumbling-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127485530","content_text":"What happened\nShares of Bionano Genomics (NASDAQ:BNGO) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.\nSo what\nWhen a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.\n\nImage source: Getty Images.\nSaphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes). Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly one-third.\nBionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.\nNow what\nOne of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.\nBionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.","news_type":1,"symbols_score_info":{"BNGO":0.9}},"isVote":1,"tweetType":1,"viewCount":829,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}